DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks 
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
NY Times Challenges Trump Administration Subpoenas Over Air Force One Report 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
NEW YORK, Jan. 22, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased MannKind Corp. (Nasdaq:MNKD) securities between August 10, 2015 and January 5, 2016.
Click here to learn about the case: http://docs.wongesq.com/MNKD-Info-Request-Form-1078. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period Defendants issued false and misleading statements and/or failed to disclose that: (1) contrary to Defendants’ assurances, the mandated pulmonary testing or spirometry was still a significant issue impeding sales of Afrezza, the Company’s rapid-acting insulin; and (2) as a result, Defendants’ statements about MannKind’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in MannKind you have until March 15, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/MNKD-Info-Request-Form-1078.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
